




The Sleeve with Reflux and Recurrent Weight Gain – Conversion to RYGB



Almino Cardoso Ramos MD MSc, PhD, FACS, FASMBS, FIFSO









President Brazilian Society for Bariatric and Metabolic Surgery –

SBCBM - 2013-2014



Consultant Surgeon Weight Loss Journey – Ecuador Consultant Surgeon Elias Ortiz & Co - Mexico





No disclosures related to this presentation







Session 3.2.1 – 2:00pm – Revisional Surgery

Chair: Muffazal Lakdawala Moderator: Almino Ramos

Part I

Sleeve Gastrectomy

Moderators: Gerhard Prager, Kelvin Higa

Options with recurrent weight gain after ESG, Manoel Galvao Neto 6 min

Debate: The Sleeve with Reflux and Recurrent Weight Gain

Hybrid Procedures: Michel Gagner 6 min

RYGB: Almino Ramos 6 min

OAGB: Chetan Parmar 6 min

SADI-S: Antonio Torres 6 min

Other Sleeve Plus Procedures: TBA 6 min

Sum up 6 mins



Conversions in Sleeve Gastrectomy

- ✓ Gastroesophageal Reflux
 - ✓ With or without Hiatal Hernia
- ✓ Suboptimal weight results
 - ✓ Weight recurrence
 - ✓ Insufficient weight loss
- ✓ Mechanical complications Strictures



√ Fistula/Leak

Conversions in Sleeve Gastrectomy

- ✓ Gastroesophageal Reflux
 - ✓ With or without Hiatal Hernia
- ✓ Suboptimal weight results
 - ✓ Weight recurrence
 - ✓ Insufficient weight loss







Conversion from SG to RYGB Is it safe?



SURGERY FOR OBESITY
AND RELATED DISEASE

Surgery for Obesity and Related Diseases ■ (2019) 1–6

Original article

Conversion of sleeve gastrectomy to Roux-en-Y gastric bypass for complications: outcomes from a tertiary referral center in the Middle East

Juan S. Barajas-Gamboa, M.D.^a, Joshua Landreneau, M.D.^b, Carlos Abril, M.D.^a, Javed Raza, M.D.^a, Ricard Corcelles, M.D.^{a,c}, Matthew Kroh, M.D.^{a,b,c,*}

• **Conclusion:** In this series, representing the largest reported single-center experience in the Middle East, conversion of SG to RYGB was safe and effective for the treatment of symptoms and mechanical complications after SG.





Conversion of sleeve gastrectomy to Roux-en-Y gastric bypass for complications: outcomes from a tertiary referral center in the Middle East

Table 2 Procedural details and outcomes

Estimated blood loss (\leq 25 mL), n (%) 46 (97.8) Technique for GJ anastomosis Hand-sewn, n (%) 39 (82.9) Circular-stapled EEA, n (%) 8 (17.1) Length of stay, d, median (IQR) 3 (2–5) Complications within 30 d, n (%) Superficial SSI 2 (4.2) Leak 1 (2.1) Gastrointestinal hemorrhage 1 (2.1) Reoperation 2 (4.2) Readmission 5 (10.6) BMI at 12 mo postoperatively, kg/m², median (IQR)	Procedural details and outcomes	
Estimated blood loss (\leq 25 mL), n (%) 46 (97.8) Technique for GJ anastomosis Hand-sewn, n (%) 39 (82.9) Circular-stapled EEA, n (%) 8 (17.1) Length of stay, d, median (IQR) 3 (2–5) Complications within 30 d, n (%) Superficial SSI 2 (4.2) Leak 1 (2.1) Gastrointestinal hemorrhage 1 (2.1) Reoperation 2 (4.2) Readmission 5 (10.6) BMI at 12 mo postoperatively, kg/m², median (IQR)	Successful laparoscopic approach, n (%)	47 (100)
Technique for GJ anastomosis Hand-sewn, n (%) Circular-stapled EEA, n (%) Length of stay, d, median (IQR) Complications within 30 d, n (%) Superficial SSI Leak Gastrointestinal hemorrhage Reoperation Readmission BMI at 12 mo postoperatively, kg/m², median (IQR) 39 (82.9) 8 (17.1) 3 (2–5) 2 (4.2) 1 (2.1) 5 (10.6) 2 (4.2) 5 (10.6)	Operative time, min, mean \pm SD	203 ± 48
Hand-sewn, n (%) Circular-stapled EEA, n (%) Length of stay, d, median (IQR) Superficial SSI Leak Gastrointestinal hemorrhage Reoperation Readmission BMI at 12 mo postoperatively, kg/m², median (IQR) 39 (82.9) 8 (17.1) 8 (17.1) 2 (4.2) 1 (2.1) 1 (2.1) 5 (10.6) 29 (23–39 10 (IQR)	Estimated blood loss (≤ 25 mL), n (%)	46 (97.8)
Circular-stapled EEA, n (%) 8 (17.1) Length of stay, d, median (IQR) 3 (2–5) Complications within 30 d, n (%) Superficial SSI 2 (4.2) Leak 1 (2.1) Gastrointestinal hemorrhage 1 (2.1) Reoperation 2 (4.2) Readmission 5 (10.6) BMI at 12 mo postoperatively, kg/m², median (IQR)	Technique for GJ anastomosis	
Length of stay, d, median (IQR) Complications within 30 d, n (%) Superficial SSI Leak Gastrointestinal hemorrhage Reoperation Readmission BMI at 12 mo postoperatively, kg/m², median (IQR) 3 (2–5) 2 (4.2) 1 (2.1) 2 (4.2) 5 (10.6) 2 (4.2)	Hand-sewn, n (%)	39 (82.9)
Complications within 30 d, n (%) Superficial SSI Leak Gastrointestinal hemorrhage Reoperation Readmission BMI at 12 mo postoperatively, kg/m², median (IQR) 2 (4.2) 1 (2.1) 2 (4.2) 5 (10.6) 2 (23–39)	Circular-stapled EEA, n (%)	8 (17.1)
Superficial SSI Leak Gastrointestinal hemorrhage Reoperation Readmission BMI at 12 mo postoperatively, kg/m², median (IQR) 2 (4.2) 1 (2.1) 2 (4.2) 5 (10.6) 2 (4.2) 2 (4.2) 2 (4.2) 2 (4.2) 2 (4.2) 2 (4.2) 2 (4.2)	Length of stay, d, median (IQR)	3 (2–5)
Leak Gastrointestinal hemorrhage Reoperation Readmission BMI at 12 mo postoperatively, kg/m², median (IQR) 1 (2.1) 2 (4.2) 5 (10.6) 29 (23–39)	Complications within 30 d, n (%)	
Gastrointestinal hemorrhage 1 (2.1) Reoperation 2 (4.2) Readmission 5 (10.6) BMI at 12 mo postoperatively, kg/m², median (IQR)	Superficial SSI	2 (4.2)
Reoperation $2 (4.2)$ Readmission $5 (10.6)$ BMI at 12 mo postoperatively, kg/m ² , median (IQR)	Leak	1 (2.1)
Readmission 5 (10.6) BMI at 12 mo postoperatively, kg/m², median (IQR) 29 (23–39)	Gastrointestinal hemorrhage	1 (2.1)
BMI at 12 mo postoperatively, kg/m ² , median (IQR)	Reoperation	2 (4.2)
(IQR)	Readmission	5 (10.6)
	BMI at 12 mo postoperatively, kg/m ² , median	29 (23–39)
$\mathbf{D}_{\mathbf{r},\mathbf{r},\mathbf{r},\mathbf{r},\mathbf{r},\mathbf{r},\mathbf{r},\mathbf{r}$	(IQR)	
Duration of follow-up, mo, median (IQR) 1/(4–26)	Duration of follow-up, mo, median (IQR)	17 (4–26)
Mortality, n (%) 0 (0)	Mortality, n (%)	0 (0)

SD = standard deviation; GJ = gastrojejunal; EEA = end-to-end, IQR = interquartile range; SSI = surgical site infection, BMI = body mass index.

Successful procedure 100%

No/few conversion to open

Estimated operative time: 3 h

Minimal blood loss

GJ: Manual, Linear or Circular

Hospitalization 2-3 days

Main complication: Bleeding

May be done with similar problems or

complications than a regular primary LSG

Barajas-Gamboa JS et al. Surg Obes Relat Dis.

2019;15(10):1690-1695.









CLINICAL RESEARCH

Conversion from Sleeve Gastrectomy to Roux-en-Y Gastric Bypass—Indications and Outcome

Felix B. Langer · Arthur Bohdjalian · Soheila Shakeri-Leidenmühler · Sebastian F. Schoppmann · Johannes Zacherl · Gerhard Prager

 Conclusion: Conversion to RYGB is an effective treatment for weight regain or intractable reflux symptoms following SG. Thus, SG can be performed, intended as sole and definitive bariatric intervention, with conversion from SG to RYGB as an exit strategy for these complications.







Table 2 Data on indications and weight loss outcome for laparoscopic conversion from Sleeve gastrectomy (SG) to Roux-en-Y gastric bypass (RYGB)

Weight SG (kg)	Nadir Weight (kg)	Weight RYGB (kg)	EWL (%)	Interval SG-RYGB (months)	Weight loss ^a (kg)	Follow-up (months)
Reflux						
120	65	65	98	15	10	62
120	95	103	36	70	14	2
110	65	77	63	33	5	14
Weight rega	in					
167	130	146	28	54	17	24
157	140	178	-27	24	20	52
100	82	104	-10	31	25	42
115	75	88	63	36	6	7
214	167	184	21	32	8	1

^a Weight loss starting from conversion to gastric bypass



Langer FB et al. Obes Surg. 2010;20(7):835-40.






Weight Loss, Weight Regain and Conversions to Roux-en-Y Gastric Bypass 10-Year Results of Laparoscopic Sleeve Gastrectomy

Weight Loss, Weight Regain and Conversions to Roux-en-Y Gastric Bypass - 10-Year Results of Laparoscopic Sleeve Gastrectomy

D.M. Felsenreich, F.B. Langer, R. Kefurt, P. Panhofer, M. Schermann, P. Beckerhin, C. Sperker, G. Prager




• Conclusions: Within a long-term follow-up of 10 years or more after SG, a high incidence of both significant weight regain and intractable reflux was observed leading to conversion - most commonly to Roux-en-Y gastric bypass.





Weight Loss, Weight Regain and Conversions to Roux-en-Y Gastric Bypass

- 10-Year Results of Laparoscopic Sleeve Gastrectomy





• Felsenreich DM et al. Surg Obes Relat Dis. 2016;12(9):1655-1662.



Elias Ortiz & Company

Weight Loss, Weight Regain and Conversions to Roux-en-Y Gastric Bypass 10-Year Results of Laparoscopic Sleeve Gastrectomy

TABLE 1 Patient characteristics and history of weight

	All patients (n=49)**	Non- conversion (n=32)*	Weight regain (n=11)	Reflux (n= 6)
SG Median Age OP (years) Sex (female) in %	40.4 (R 15-66) 80	42.0 (R 17-66) 84	39.0 (R 15-65) 73	37.2 (R 32-53) 83.0
Weight (kg) BMI (kg/m2) Superobese BMI >50 (%)	137.1 ±28.5	137.2 ±28.5	133.3 ±27.3	139.0±36.6
	48.9 ±9.4	49.7 ±9.9	47.1 ±9.4	46.8 ±7.4
	36.7	44.0	27.3	16.6
Nadir Weight (kg) BMI (kg/m2) Change BMI (kg/m2) EWL (%) Median post OP time (months)	86.7 ±20.5	86.0 ±19.1	93.7 ±26.0	74.3 ±7.2
	31.0 ±6.2	31.0 ±6.2	32.8 ±6.5	26.4 ±2.5
	17.4 ±8.1	19.2 ±8.5	11.8 ±5.8	17.5 ±3.5
	71.3 ±24.8	75.30 ±19.8	63.1 ±29.3	67.4 ±39.9
	12 (R 12-120)	12 (R 12-120)	12 (R 12-48)	12 (R 12-48)
Conversion Weight (kg) BMI (kg/m2) Change BMI (kg/m2) EWL (%) Median post OP time (months)		an	115.3 ±22.7 40.6 ±5.1 4.9 ±11.5 22.0 ±30.3 48 (R 24-84)	102.3 ±30.8 36.2 ±9.7 14.2 ±10.1 37.9 ±56.1 24 (R 12-84)
Ten years Weight (Today) in kg BMI (Today) in kg/m2 Change BMI (kg/m2) EWL (Today) in % Median post OP Time (months)	98.1 ±21.3	100.8 ±22.1	98.0 ±20.5	80.0 ±5.9
	35.5 ±7.0	36.4 ±7.4	34.7 ±5.7	28.7 ±4.7
	13.8 ±10.0	13.9 ±10.1	9.9 ±6.4	15.3 ±5.0
	54.0 ±26.7	52.5 ±24.8	52.8 ±32.7	73.5 ±20.2
	130 (R 120-152)	128 (R 122-150)	124 (R 121-152)	134 (R 123-151)

Felsenreich DM et al. Surg Obes Relat Dis

2016;12(9):1655-1662.

Elias Ortiz & Company
MEXICO WEIGHT LOSS SPECIALISTS



Abbreviations: BMI: Body Mass Index; EWL: Excess Weight Loss; SG: Sleeve Gastrectomy: R:

Range



OBES SURG DOI 10.1007/s11695-017-2542-8



ORIGINAL CONTRIBUTIONS

Conversion of Sleeve Gastrectomy to Roux-en-Y Gastric Bypass is Effective for Gastro-Oesophageal Reflux Disease but not for Further Weight Loss

Chetan D Parmar¹ · Kamal K Mahawar¹ · Maureen Boyle¹ · Norbert Schroeder¹ · Shlok Balupuri¹ · Peter K Small¹

• **Conclusion:** This study demonstrates that conversion of SG to RYGB is effective for GERD symptoms but not for further weight loss, which was modest in both groups. Future studies need to examine the best revisional procedure for IWL/WR after SG.







Table 2 Weight loss in patients converted for GERD

Parameters	Weight before SG	Weight at conversion to RYGB	6 months after RYGB $(N = 10)$	12 months after RYGB $(N = 10)$	24 months after RYGB $(N = 7)$
Mean weight (kg)	130.8 (95.8–199.6)	87.5 (56.8–125.7)	82.1 (53.6–113)	85.9 (59.8–102)	79.1 (51–105)
Mean BMI (kg/m ²)	45.8 (37.6–66.7)	30.5 (23.7–42)	28.6 (21.4–37.7)	29.5 (24.2–33.7)	28.5 (18.8–34.3)
EWL (%)	-	75.8 (51.8–109.5)	83.5 (48.8–114)	77.8 (38.7–105.8)	82.1 (18.5–124)

GERD gastro-esophageal reflux disease, SG sleeve gastrectomy, RYGB Roux-en-Y gastric bypass, BMI body mass index, EWL excess weight loss

Conversion from SG to RYGB due to GERD leads to excellent WL









Table 3 Weight loss in patients converted for IWL/WR

Parameters	Weight before SG	Weight at conversion to RYGB	6 months post RYGB $(N = 8)$	12 months after RYGB $(N = 11)$	24 months after RYGB $(N = 7)$
Mean weight (kg) Mean BMI (kg/m²)	152.1 (115.2–224) 53.1 (42.3–66.2)	123.8 (82.8–173.1) 43.3 (34.6–54.4)	109.9 (72.2–163) 38.2 (31–46.1)	114.6 (70.6–167) 39.9 (30.4–47.6)	116.1 (88–162)
EWL (%)	- -	36.1 (24.4–45.5)	49.9 (32.8–68.9)	49.5 (33.7–72.5)	40.8 (32.3–48.1) 46 (32.3–57.7)

IWL inadequate weight loss, *WR* weight regain, *SG* sleeve gastrectomy, *RYGB* Roux-en-Y gastric bypass, *BMI* body mass index, *EWL* excess weight loss

Conversion from SG to RYGB due to IWL/WR has more limited WL



Parmar CD et al. Obes Surg. 2017 Jul;27(7):1651-1658.





 Table 5
 Weight loss outcomes in studies reporting on conversion of SG to RYGB for IWL/WR

Study characteristics	Year of publication Evidence of level Mean Time to Conversion	Pre-conversion characteristics	Bypass limbs Mortality Early complication Late complication	Weight loss outcomes After conversion
Abdemur et al. [9]	2016	BMI at SG: NA	Limb lengths: NA	Final EWL: 47.0 (9.7–82.4)
Jan. 2004–Aug 2014 N: 7 Sex: NA Mean age: NA	Level IV NA	BMI at conversion: NA EWL at conversion: 17.8.8 (10.0–28.2) %	Mortality: 0 Early complication: 0 Late complication: 1 perforated MU	% Mean FU: 9.8 months
Alsabah et al. [4] $2009-2012$ $N = 12$	2016 Level IV NA	BMI at SG: 52.0 kg/m ² BMI at conversion: 41.0 kg/m ² EWL at conversion: 37.9%	BPL 70 cm; AL 150 cm Mortality: 0 Early complications: 0	Final EWI: 61.3% at 1 year. BMI came down to 36.0
Sex: 10 females Mean age: 34 years			Late complications: 0	Authors found no significant difference in weight loss between re-sleeve and RYGB at 1 year after revision
Carmeli et al. [16]	2015	BMI at SG: 44.5 kg/m ²	NA	Final EWI: 66.6% Ifter
Dec 2006–Nov 2012	Level IV	BMI at conversion: 39.8 kg/m ²	Mortality: 0	36 month.
N = 10	36.0 months	EWL at conversion: 25.0%	Early complication: 0	BMI down to 30.2%
Sex: NA Mean age: NA			Late complication: 1 MU related to aspirin	Weight loss superior with DS.
Gautier et al. [2]	2013	BMI at SG: 58.2 kg/m ²	BPL 70 cm, AL 120–150 cm.	Final EWI: 59.0%. BMI came
Jun 2005–Dec 2010	Level IV	BMI at conversion: 43.7 kg/m ²	Mortality: 0	down
N = 9	24.3 months	EWL at conversion: 41.0%	Early complication: NA	to 38.1 kg/m^2
Sex: NA Age: 36.8			Late complication: NA	
Langer et al. [5]	2010	BMI at SG: 49.0 kg/m ²	BPL 80 cm, AL 150 cm. One was	Final EWL: 35% after a mean
Dec 2002 to	Level IV	BMI at conversion: 45.6	banded bypass	FU of
Sept 2009	35.4 months	EWL at conversion: 15.0%	Mortality: NA	25.2 (1–52) months
N = 5			Early complication: NA	BMI came down to
Sex: 1/5 (20.0% fe-			Late complication: NA	40.6 kg/m^2
male)				
Mean Age: 36.2 yeas				

Parmar CD et al. Obes Surg. 201 Jul;27(7):1651-1658.



Conversion from SG to RYGB with incomplete resolution of GERD

Table 6 GERD outcomes in studies reporting on conversion of SG to RYGB for GERD

Study characteristics	Year of publication Evidence of level Mean time to conversion	Complete resolution o GERD symptoms	Partial resolution of GERD symptoms (needing PPI)
Abdemur et al. [9]	2016	7	2
Jan 2004–Aug 2014	Level IV		
N: 9	NA		
Sex: NA			
Mean age: NA			
Gautier et al. [2]	2013	6	0
Jun 2005–2010	Level IV		
N: 6	28.1 months		
Sex: NA			
Mean age: 44			
Langer et al. [5]	2010	3	0
Dec 2002-Sept 2009	Level IV		
N: 3	39.3 months		
Sex: 3 females			
Mean age: 35 years			
Van Rutte et al. [13]	2012	3	2
Aug 2006–July 2010	Level IV		
N: 5	NA		
Sex: NA			
Mean Age: NA			
Hendricks [19]	2015	3	1
2005–2013	Level IV		
N: 4	30 months (9–56)		
Sex: NA			
Mean age: NA Cumulative results		22 (81. 5%)	5 (18.5%)

Improvement of GERD Is not 100% - 80%

Parmar CD et al. Obes Surg. 2017 Jul;27(7):1651-1658.



SG sleeve gastrectomy, RYGB Roux-en-Y gastric bypass, N number, GERD gastro-esophageal reflux disease, PPI proton pump inhibitor, NA not available



 Table 1
 Early and late complications after conversion of SG to RYGB

Serial No	Age/sex	Early (\leq 30-day) or late (>30-day)	Diagnosis	Management
1 ^a Conversion for IWL	70/F	Early	Bowel obstruction	Laparotomy for internal hernia
2 Conversion for GERD	46/F	Late	Marginal ulcer	Managed conservatively
3 Conversion for GERD	46/F	Late	Abdominal pain and persistent GERD	Normal CT scan and endoscopy. Patient requested referral to a closer hospital unit to avoid frequent travel
4 ^a Conversion for IWL	58/F	Late	Abdominal pain	Laparoscopy and adhesiolysis
5 Conversion for GERD	43/M	Late	Persistent GERD	Post conversion endoscopy normal. Symptoms controlled on PPI.

SG sleeve gastrectomy, RYGB Roux-en-Y gastric bypass, IWL inadequate weight loss, GERD gastro-esophageal reflux disease, F female, M male, PPI proton pump inhibitor

✓ Missed and not repaired HH

✓ Use of a large pouch





^a Needed reoperation

Indications and Mid-Term Results of Conversion from Sleeve Gastrectomy to Roux-en-Y Gastric Bypass

 Table 2
 Results after conversion

	Total, mean (range) 55/41	IWL (mean) 58/44	Reflux (mean)	Diabetes (mean)
BMI ac (kg/m ²)	35.8 (24–42.6)	38.1	32.7	34.9
%EBMILac	64.6 (36.9–104.6)	60.6	69.9	65.6
%EWLac	61.7 (34.2–103.2)	59	65.9	61.6

BMIac BMI after conversion, %EBMILac percentage of excess BMI loss after conversion, %EWLac percentage of excess weight loss after conversion



Gautier T et al. Obes Surg. 2013;23(2):212-5.







Conversion of Sleeve Gastrectomy to Roux-en-Y Gastric Bypass: An Audit of 34 Patients

And about other associated diseases?

Table 4: Evolution of comorbidities and medications use.

Variable	Before conversion	At end-point (mean follow – up -3 years)	<i>p</i> -value
Hypertension (n, %)	13 (38%)	13 (38%)	NS
No. of medications, mean ±SD	1.6 ±0.5	1.3 ±0.5	NS
Type 2 diabetes (n, %)	11 (33%)	4 (12%)	0,023
No. of medications, mean ±SD	1.5 ±1	0.5 ±0.5	0,004
Obstructive sleep apnea syndrome (n, %)	14 (41%)	11 (32%)	NS
Positive airway pressure therapy (n, %)	5 (15%)	5 (15%)	NS
GERD (n, %)	9 (26.5%)	0	0,002

SD= standard deviation; GERD= gastro esophageal reflux disease

Hypertension

T2D

Sleep Apnea

GERD

Poghosyan T et al. Surg Obes Relat Dis. 2016;12(9):1646-1651.







Revision of Sleeve Gastrectomy to Roux-en-Y Gastric Bypass: a Canadian Experience

Effectiveness

Table 1. Weight loss trends before and after revision-RYGB (n = 18)

Variable	Mean	SD	Min	Max
Mean BMI pre-SG (kg/m ²) BMI LSG	50.5	12.0	35.1	77.5
Mean BMI post-SG (kg/m ²)	40.5	10.5	25.2	60.5
Maximum Weight loss after SG (kg)	28.3	12.5	8.8	63.0
Time to Maximum Weight Loss after SG (months)	20.9	7.8	10.0	35.0
Time between SG and RYGB Conversion (months)	41.8	12.5	22.0	61.0
BMI pre-RYGB BMI RYGE	43.1	9.0	31.1	60.5
Weight Change between lowest patient weight after SG	7.4	8.7	-7.4	24.4
and weight right before revisional-RYGB (kg)				
Maximum Weight Loss after RYGB Conversion (kg)	19.3	9.4	8.1	39.6
Lowest BMI post-RYGB (kg/m ²) BMI RYGE	36.4	9.0	18.3	49.0
			7	

^{*}SD = Standard Deviation, Max = Maximum, Min = Minimum, BMI = Body Mass Index



Yorke E et al. Am J Surg. 2017;213(5):970-974.






Sleeve Gastrectomy to Gastric Bypass



s s

Sleeve to Bypass for Weight Regain









SLEEVE GASTRECTOMY CONVERTION TO GB

LISTS

Conclusions

- ✓ Safe
- **✓ Effective**
 - ✓ Adding some more weight loss
 - ✓ Improving GERD
 - **✓** Controlling other associated diseases
- ✓ Additional weight loss is limited
- **Improving of GERD is not 100%**

Thank you! Gracias! Obrigado!

Almino Cardoso Ramos ramos.almino@gmail.com







